Prokidney (PROK) Return on Capital Employed (2021 - 2026)
Prokidney (PROK) reported Return on Capital Employed of 12.25% for Q1 2026, up 3510.0% year-over-year from 0.34% in Q1 2025, and down 20.65% quarter-over-quarter from 10.15% in Q4 2025.
Prokidney (PROK) Return on Capital Employed (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Return on Capital Employed data on file, last reported at 12.25% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 12.25%, up 3510.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 12.25% (up 3510.0% YoY), and the FY2025 annual result was 8.88%, up 3767.0% from the prior year.
- Return on Capital Employed fell to 12.25% in Q1 2026 per PROK's latest filing, from 10.15% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.15% in Q4 2025 and troughed at 61.29% in Q1 2022.
- A 5-year average of 36.56% and a median of 36.41% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed soared 3557 bps in 2023, then tumbled 1759 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 29.75% in 2022, then slipped by 24 bps to 36.85% in 2023, then slipped by 18 bps to 43.55% in 2024, then surged by 77 bps to 10.15% in 2025, then dropped by 21 bps to 12.25% in 2026.
- Business Quant data shows PROK's Return on Capital Employed at 12.25% in Q1 2026, 10.15% in Q4 2025, and 51.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - | -12.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.25% |
| Dec 31, 2025 | -10.15% |
| Sep 30, 2025 | -51.44% |
| Jun 30, 2025 | -50.34% |
| Mar 31, 2025 | -47.34% |
| Dec 31, 2024 | -43.55% |
| Sep 30, 2024 | -33.85% |
| Jun 30, 2024 | -36.41% |
| Mar 31, 2024 | -39.16% |
| Dec 31, 2023 | -36.85% |
| Sep 30, 2023 | -35.24% |
| Jun 30, 2023 | -31.49% |
| Mar 31, 2023 | -25.73% |
| Dec 31, 2022 | -29.75% |
| Sep 30, 2022 | -32.76% |
| Jun 30, 2022 | -43.88% |
| Mar 31, 2022 | -61.29% |
| Dec 31, 2021 | -14.54% |